Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Urogen Pharma ( (URGN) ) has shared an update.
On June 30, 2025, UroGen Pharma’s Board of Directors approved special bonuses for key executives, recognizing their leadership in achieving FDA approval for ZUSDURI, a treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer. This approval marks a significant milestone for the company, potentially enhancing its market position and benefiting stakeholders by expanding its therapeutic offerings.
The most recent analyst rating on (URGN) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Urogen Pharma stock, see the URGN Stock Forecast page.
Spark’s Take on URGN Stock
According to Spark, TipRanks’ AI Analyst, URGN is a Neutral.
The most significant factor is the FDA approval of ZUSDURI, which strongly boosts growth potential. However, financial stability concerns and valuation risks weigh down the score. Positive technical indicators and strategic advancements offset some risks.
To see Spark’s full report on URGN stock, click here.
More about Urogen Pharma
UroGen Pharma Ltd. operates in the pharmaceutical industry, focusing on developing treatments for urological conditions. The company is known for its innovative therapies, particularly in addressing bladder cancer.
Average Trading Volume: 2,960,719
Technical Sentiment Signal: Buy
Current Market Cap: $600.3M
For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.